Can EYİGÖR, Oğuzhan YENİAY, Derya Guner, Burcu OZALP HORSANALI

Kronik Ağrıda Nöromodülasyon Tedavileri ve Klinik Sonuçlar: Tek Merkez Deneyimi

Nöromodülasyon terapileri, çeşitli etiyolojilerden kaynaklanan ağrılar için etkili tedavi seçenekleridir. Titiz bir deneme süresi ve multidisipliner değerlendirmeyi içeren dikkatli hasta seçimi esastır. Bu makale, nöromodülasyon terapilerinin ortak endikasyonlarını, etkinliğini ve 3 ile 6 aya kadar olan hasta takiplerinin klinik sonuçlarını tartışmaktadır. Yöntem: Dört servikal omurilik stimülasyonu (SCS), onaltı torasik SCS ve üç sakral nöromodülasyon (SNS) olmak üzere toplam 23 hastanın 6 aylık klinik takipleri yapıldı. Sonuç ölçütleri ağrı (görsel analog skala [VAS]), yaşam kalitesi (36 Maddelik Kısa Form Anketi [SF-36]), Oswestry Engellilik İndeksi (ODI) ve Leeds Nöropatik Semptomlar ve Belirtiler Değerlendirmesi (LANSS) Nöropatik Ağrı Ölçeği Anketi idi. Aşırı aktif mesane değerlendirme formu ve pelvik ağrı etkisi anketi SNS uygulanacak hastalarda ayrıca değerlendirildi. Bulgular: Başvuru ile üçüncü ve altıncı ay takipleri arasında SF- 36 parametreleri, VAS, ODI ve LANSS puanları açısından anlamlı fark vardı (p

Neuromodulation Therapy in Chronic Pain and Clinical Outcomes: A Single-Center Experience

Neuromodulation therapies are successful treatment options for pain raised from a variety of etiologies. Careful patient selection and multidisciplinary evaluation are essential to achieve the best outcome. We aimed to discuss the common indications of neuromodulation therapies, efficacy, and clinical outcomes of patient follow-up to 3 and 6 months. Methods: Twentytree patients completed the 6-month followup: four underwent cervical spinal cord stimulation (SCS), sixteen had thoracic SCS, and three had sacral neuromodulation (SNS). Outcome measures were pain (visual analog scale[VAS]), quality of life (36-Item Short Form Survey [SF-36]), Oswestry Disability Index [ODI]), and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) neuropathic pain scale questionnaire. The overactive bladder assessment form and the pelvic pain impact questionnaire were performed on patients who would undergo SNS. Results: A significant difference was shown in regards to the scores of the VAS, SF-36 parameters, ODI, and LANSS between admission and the third and sixth-month follow-ups (p

PDF

___

1. Cruccu G, Garcia Larrea L, Hansson P, et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol 2016;23(10):1489-99.
2. Shamji MF, De Vos C, Sharan A. The advancing role of neuromodulation for the management of chronic treatmentrefractory pain. Neurosurgery 2017;80(3S):108-13.
3. Melzack R, Wall PD. Pain mechanisms: A new theory. Science 1965;150(3699):971-9.
4. Moisset X, Lanteri-Minet M, Fontaine D. Neurostimulation methods in the treatment of chronic pain. J Neural Transm 2020;127(4):673-86.
5. De Wachter S, Knowles CH, Elterman DS, et al. New technologies and applications in sacral neuromodulation: An update. Adv Ther 2020;37(2):637-43.
6. Han A, Carayannopoulos AG. Spinal cord stimulation: The use of neuromodulation for treatment of chronic pain. R I Med 2020;103(4):23-6.
7. Moisset X, Bouhassira D, Couturier JA, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol 2020;176(5):325-52.
8. Fontaine D. Spinal cord stimulation for neuropathic pain. Rev Neurol 2021;177(7):838-42.
9. Cameron T. Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: A 20-year literature review. J Neurosurg 2004;100(3 Suppl Spine):254-67.
10. Daniell JR, Osti OL. Failed back surgery syndrome: A review article. Asian Spine J 2018;12(2):372-9.
11. Van Heteren EPZ, Van Roosendaal BKW, Van Gorp EJJ, et al. Spinal cord stimulation with additional peripheral nerve/field stimulation vs spinal cord stimulation alone on back pain and quality of life in patients with failed back surgery syndrome. Neuromodulation 2022;26:S1094-7159
12. Rigoard P, Basu S, Desai M, et al. Multicolumn spinal cord stimulation for predominant back pain in failed back surgery syndrome patients: A multicenter randomized controlled trial. Pain 2019;160(6):1410-20.
13. Deer TR, Skaribas IM, Haider N, et al. Effectiveness of cervical spinal cord stimulation for the management of chronic pain. Neuromodulation 2014;17(3):265-71.
14. Chivukula S, Tempel ZJ, Weiner GM, et al. Cervical and cervicomedullary spinal cord stimulation for chronic pain: Efficacy and outcomes. Clin Neurol Neurosurg 2014;127:33- 41.
15. Raut R, Shams S, Rasheed M, Niaz A, Mehdi W, Chaurasia B. Spinal cord stimulation in the treatment of phantom limb pain: A case report and review of literature. Neurol India 2021;69(1):157-60.
16. Al-Kaisy A, Palmisani S, Pang D, et al. Prospective, randomized, sham-control, double blind, crossover trial of subthreshold spinal cord stimulation at various kilohertz frequencies in subjects suffering from failed back surgery syndrome (SCS frequency study). Neuromodulation 2018;21(5):457-65.
17. Amin K, Moskowitz D, Kobashi KC, Lee UJ, Lucioni A. Do patients discontinue overactive bladder medications after sacral neuromodulation? J Urol 2019;201(5):973-8.
18. Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Central hypersensitivity in chronic pain: Mechanisms and clinical implications. Phys Med Rehabil Clin N Am 2006;17(2):287- 302.
19. Xiao B, Dubin AE, Bursulaya B, Viswanath V, Jegla TJ, Patapoutian A. Identification of transmembrane domain 5 as a critical molecular determinant of menthol sensitivity in mammalian TRPA1 channels. J Neurosci 2008;28(39):9640- 51.
20. Meuwissen KPV, Van der Toorn A, Gu JW, Zhang TC, Dijkhuizen RM, Joosten EAJ. Active recharge burst and tonic spinal cord stimulation engage different supraspinal mechanisms: A functional magnetic resonance imaging study in peripherally injured chronic neuropathic rats. Pain Pract 2020;20(5):510- 21.
21. Deogaonkar M, Sharma M, Oluigbo C, et al. Spinal cord stimulation (SCS) and functional magnetic resonance imaging (fMRI): modulation of cortical connectivity with therapeutic SCS. Neuromodulation 2016;19(2):142-53.